Myomectomy Market in North America to Dominate Due to High Fibroid Prevalence

As women’s reproductive healthcare gains greater global attention, uterine fibroids—a common but often under-discussed condition—are emerging as a significant medical concern. Affecting an estimated 70–80% of women by the age of 50, fibroids can lead to serious symptoms including excessive menstrual bleeding, pelvic pain, and compromised fertility. Myomectomy, a surgical procedure aimed at removing fibroids while preserving the uterus, is increasingly becoming the preferred alternative to hysterectomy. As medical professionals and patients alike place growing emphasis on fertility preservation and minimally invasive treatment options, the myomectomy market is poised for strong growth. According to market data, the global myomectomy market stood at US$ 642.1 Mn in 2024, and is projected to reach US$ 1,430.7 Mn by 2035, advancing at a CAGR of 7.5% from 2025 to 2035.

Access key findings and insights from our Report in this sample

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86660

The Clinical and Economic Need for Myomectomy

The rise in demand for myomectomy stems from a growing clinical need to address uterine fibroids in a way that maintains reproductive potential. With shifting societal norms, more women are delaying childbirth until their 30s or 40s—coincidentally, the age range most affected by fibroids. For these women, preserving the uterus is often of paramount importance. As a uterus-sparing surgical option, myomectomy is increasingly considered superior to hysterectomy, especially among patients prioritizing fertility or concerned about psychological and social implications tied to uterus removal.

In addition to clinical benefits, the rising popularity of myomectomy is also economically driven. With healthcare systems around the world emphasizing patient-centered care, cost-effectiveness, and recovery time, minimally invasive myomectomy procedures, such as laparoscopic and robotic approaches, align well with these objectives. However, accessibility remains a barrier in low- and middle-income nations due to the high costs and limited availability of specialized surgical expertise.

Segmentation by Procedure Type: Open Myomectomy Still Leading

The myomectomy market can be segmented into four primary procedure types: open myomectomy, laparoscopic myomectomy, hysteroscopic myomectomy, and robotic laparoscopic myomectomy. Among these, open myomectomy continues to dominate, especially for large or multiple fibroids that deeply penetrate uterine muscle. This method offers better visibility and maneuverability for surgeons handling complex cases and remains widely practiced in both developed and developing countries.

Despite the longer recovery period and higher complication rates associated with open surgery, it is often the only viable option in certain cases. For instance, in countries with limited access to robotic or laparoscopic tools, open myomectomy becomes the default. Moreover, a 2023 study published in Obstetrics & Gynecology International indicated that approximately 65% of patients with fibroids larger than 8 cm underwent open procedures due to the surgery’s complexity and limited alternative options.

In contrast, laparoscopic and robotic myomectomy are gaining popularity in urban centers of high-income countries due to their reduced hospitalization times, lower pain levels, and faster return to normal activities. However, adoption is currently limited by their higher costs, need for extensive surgical training, and availability of advanced surgical systems.

Product Landscape: Technology as a Catalyst

The product segment supporting myomectomy procedures includes a variety of specialized surgical instruments such as laparoscopic power morcellators, harmonic scalpels, laparoscopic vessel sealers, hysteroscopic resectoscopes, myomectomy forceps, and myoma screw instruments. Also included are other essential tools like retractors, myoma knives, and speculums.

Technological innovations in this area are improving precision, reducing surgical time, and enhancing safety. Noteworthy is the Sonata System by Gynesonics, which combines real-time intrauterine ultrasound guidance with radiofrequency ablation. The September 2024 release of the SMART OS 2.4 software for the Sonata System marks a significant leap forward in non-invasive fibroid treatment. It enables fibroid ablation without incisions, using graphical overlays and live imaging to improve targeting accuracy.

Similarly, Intuitive Surgical’s FDA-cleared da Vinci 5 robotic system, announced in March 2024, represents a milestone in robotic-assisted myomectomy. This next-generation system enhances tactile feedback, surgical dexterity, and precision—capabilities that are particularly beneficial in myomectomy where uterine reconstruction is crucial for future fertility.

Want to know more? Get in touch now

https://www.transparencymarketresearch.com/contact-us.html

Geographic Analysis: North America Takes the Lead

North America commands the largest share in the global myomectomy market, with the U.S. at the forefront due to high fibroid prevalence—particularly among African-American women, who are nearly twice as likely to develop fibroids compared to white women. The region also benefits from high awareness, advanced healthcare infrastructure, and widespread availability of skilled gynecologic surgeons. Furthermore, strong reimbursement frameworks from providers like CMS (Centers for Medicare & Medicaid Services) help promote the adoption of both traditional and minimally invasive procedures.

Research institutions such as the Mayo Clinic and the Cleveland Clinic play a pivotal role in pioneering treatment innovations and setting clinical guidelines for fibroid management. Public health campaigns, women’s health advocacy, and increased screening further contribute to early diagnosis and timely surgical intervention.

Outside North America, Europe also holds a notable share of the market, with countries like Germany, France, and the UK showing strong adoption of minimally invasive technologies. Meanwhile, Asia Pacific is an emerging hotspot due to rising awareness, growing health expenditure, and improving surgical infrastructure, although affordability remains a limiting factor.

End-User Analysis: From Hospitals to Ambulatory Surgical Centers

While hospitals and specialty clinics remain the primary providers of myomectomy procedures, the shift toward ambulatory surgical centers (ASCs) is becoming increasingly apparent. These outpatient settings offer lower costs, reduced infection risks, and quicker discharge times, making them attractive to both patients and payers. With advancements in laparoscopic and robotic systems that allow for same-day discharge, ASCs are expected to see growing volumes of myomectomy procedures in the coming years.

Competitive Landscape: Innovation and Expansion Strategies

Leading players in the myomectomy market are pursuing a mix of organic and inorganic strategies to retain competitive advantage. Companies such as Medtronic, Stryker Corporation, Hologic, Inc., Intuitive Surgical, Olympus Corporation, and Gynesonics are heavily investing in R&D, with a focus on improving imaging precision, reducing invasiveness, and expanding their reach in emerging markets.

Collaborations with academic institutions, strategic acquisitions, and regional expansions are also common tactics. These partnerships enable companies to harness the latest clinical findings, streamline regulatory approvals, and introduce customized solutions tailored to regional healthcare demands.

Explore our report to uncover in-depth insights
https://www.transparencymarketresearch.com/myomectomy-market.html

Conclusion: The Future of Fibroid Treatment

As the landscape of women’s health evolves, myomectomy is poised to play an increasingly prominent role in addressing fibroids while supporting reproductive goals. The convergence of clinical need, patient preference, and technological innovation is fostering a market environment ripe for growth. Despite challenges such as cost and access disparity in lower-income regions, the global momentum toward uterus-preserving, minimally invasive treatments is undeniable.

The coming decade will see continued efforts to enhance procedural safety, optimize outcomes, and ensure equitable access—transforming myomectomy from a specialized surgery into a mainstream reproductive health solution for millions of women worldwide.

 

Read More

Myomectomy Market: Impact of Rising Fibroid Prevalence

 The global myomectomy market is experiencing sustained expansion as awareness of uterine fibroids and demand for fertility-sparing treatments increase among women of reproductive age. Uterine fibroids, benign smooth-muscle tumors of the uterus, affect an estimated seventy to eighty percent of women by the age of fifty, often causing symptoms such as heavy menstrual bleeding, pelvic pain, and reproductive challenges. Myomectomy—a surgical intervention that removes fibroids while preserving the uterus—has emerged as the treatment of choice for women who wish to retain their fertility or avoid the physical and psychological effects of hysterectomy. In 2024, the market reached six hundred forty-two point one million United States dollars and is projected to grow at a compound annual growth rate of seven point five percent from 2025 through 2035, ultimately reaching one billion four hundred thirty million seven hundred thousand United States dollars by the end of that period. This growth trajectory reflects not only the rising incidence of fibroids but also the continuous innovation in surgical approaches and devices that improve patient outcomes and reduce recovery times.

Visit our report to discover a deeper understanding of the findings -

https://www.transparencymarketresearch.com/myomectomy-market.html

Key Market Drivers

A principal factor propelling market expansion is the increasing prevalence of uterine fibroids among women aged thirty to fifty. As more patients undergo routine gynecological examinations and benefit from advanced diagnostic imaging modalities—such as transvaginal ultrasound and magnetic resonance imaging—the detection rate of asymptomatic and symptomatic fibroids has risen substantially. Heightened health-awareness campaigns and patient advocacy initiatives have further encouraged women to seek timely medical intervention, leading to greater demand for myomectomy procedures. Another significant driver is the growing preference for uterus-preserving surgeries. With many women delaying marriage and childbirth into their thirties and forties, fertility preservation has become a paramount concern. Surveys indicate that women in the twenty-five to forty age group overwhelmingly choose myomectomy over hysterectomy to safeguard their reproductive potential and maintain bodily integrity. The psychosocial value of retaining the uterus, combined with improved surgical options that minimize scarring and hospital stays, has shifted both clinician recommendations and patient choices toward myomectomy.

Technological Innovations and Procedure Mix

Open myomectomy remains the most widely utilized approach, particularly for the removal of large, multiple, or deeply embedded fibroids. This traditional method provides surgeons with enhanced operative exposure and visibility, facilitating complete excision of fibroids and meticulous uterine reconstruction. However, minimally invasive techniques are rapidly gaining ground. Laparoscopic myomectomy employs small abdominal incisions and specialized instruments, offering reduced postoperative pain and quicker return to daily activities. Hysteroscopic myomectomy accesses the uterus through the cervix, making it ideal for submucosal fibroids and obviating external incisions. Robotic-assisted laparoscopic myomectomy represents the cutting edge of this evolution, combining three-dimensional visualization and articulated instrument control to enhance precision and dexterity. While the adoption of robotic platforms has been constrained by high acquisition and maintenance costs, their benefits in complex cases and patient satisfaction are driving investment in training and infrastructure, especially in developed healthcare systems.

Open Myomectomy as the Gold Standard

Despite the appeal of minimally invasive approaches, open myomectomy continues to hold the leading share of procedures worldwide. In instances where fibroids exceed eight centimeters in diameter, are multiple in number, or penetrate deeply into the uterine wall, open surgery enables thorough removal with lower risk of incomplete excision and recurrence. A multicenter retrospective analysis demonstrated that approximately sixty-five percent of patients presenting with large fibroids underwent open myomectomy, underscoring its indispensability in complex cases. Moreover, in low- and middle-income regions where access to advanced laparoscopic or robotic systems is limited, open surgery remains the primary—and often only—therapeutic option. Although recovery times are longer and the risk of complications such as postoperative adhesions is higher compared to minimally invasive methods, open myomectomy’s reliability and broad availability continue to sustain its dominance.

Regional Outlook and North American Leadership

North America currently commands the largest share of the global myomectomy market, driven by several interrelated factors. The United States exhibits a particularly high prevalence of uterine fibroids—up to eighty percent among African-American women by age fifty—creating substantial demand for surgical intervention. A mature healthcare infrastructure, robust reimbursement policies, and early adoption of advanced surgical technologies further support market growth. Coverage of minimally invasive myomectomy procedures by the Centers for Medicare and Medicaid Services has encouraged healthcare providers to invest in state-of-the-art equipment and surgeon training. Additionally, leading research institutions such as the Mayo Clinic and the Cleveland Clinic continuously refine surgical techniques and contribute to evidence-based practice guidelines. Patient advocacy organizations in the region also play a critical role in raising awareness, promoting early diagnosis, and facilitating access to care. While Europe and the Asia Pacific region present significant growth opportunities—driven by improving healthcare access, rising disposable incomes, and expanding surgical capacity—North America’s established ecosystem of innovation and reimbursement is likely to sustain its leadership through 2035.

Competitive Landscape and Key Players

The competitive environment in the myomectomy market is characterized by a mix of diversified medical device companies and specialized manufacturers. Major participants include Medtronic, Stryker Corporation, CONMED Corporation, INSIGHTEC, CooperSurgical Inc., Hologic, Intuitive Surgical, Karl Storz, B. Braun Melsungen AG, Richard Wolf Medical Instruments, Olympus Corporation, Minerva Surgical Inc., and Gynesonics. These organizations engage in a variety of strategic initiatives—such as product innovation, mergers and acquisitions, and geographic expansion—to strengthen their market positions. Recent product launches reflect the ongoing emphasis on minimally invasive surgery: in September 2024, Gynesonics introduced SMART OS 2.4 software for its Sonata System, enabling incision-free, ultrasound-guided ablation of fibroids. Earlier in March 2024, Intuitive Surgical secured regulatory clearance for its fifth-generation da Vinci 5 robotic system, showcasing enhancements in haptic feedback and ergonomic design. Beyond hardware and software, key players are forming partnerships with academic centers to conduct clinical studies, validate new techniques, and expedite market approval of novel devices.

Future Outlook and Conclusion

Looking ahead, the myomectomy market is poised for sustained growth, driven by an aging yet active female population, rising awareness of fibroid symptoms, and evolving patient preferences toward less invasive, fertility-preserving treatments. Continued advancements in imaging, instrumentation, and robotics are likely to lower barriers to minimally invasive surgery, extend indications for hysteroscopic and laparoscopic approaches, and improve long-term outcomes. At the same time, addressing access gaps in emerging economies through cost-effective device solutions and surgeon training programs remains a critical challenge. Market participants who successfully balance technological innovation with affordability and implement comprehensive education initiatives for both clinicians and patients will be best positioned to capture the substantial opportunities ahead. As the global healthcare community unites around the goals of optimal fibroid management and quality of life improvement, myomectomy will remain at the forefront of therapeutic strategies for women’s health.

 

 

 

 

 

 

Read More